Tonix Pharmaceuticals Announces Positive Phase 1 Results and Strategic Phase 2 Plans for TNX-4800 Lyme Disease Prophylactic

Key Highlights for Investors

• Positive Phase 1 Results: TNX-4800, a long-acting monoclonal antibody, demonstrated safety, tolerability, and pharmacokinetics supportive of approximately four months of protection against Lyme disease.
• Phase 2 Study Planned: Tonix expects to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study in the first half of 2027, pending FDA clearance.
• First-in-Class Prophylactic: TNX-4800 is positioned as a single-dose, long-acting prophylactic for Lyme disease, addressing a major unmet need in a population of 87 million at-risk Americans.
• No FDA-Approved Prophylactic or Vaccine: There are currently no FDA-approved vaccines or single-dose prophylactics for Lyme disease in the U.S.
• Rapid and Durable Protection: TNX-4800 is designed to provide immunity within two days of administration and maintain protective levels for up to four months.
• Strong Pharmacokinetic Profile: Phase 1 data showed rapid systemic absorption, long half-life (62-69 days), and quantifiable antibody levels in most subjects for up to a year.
• Upcoming Milestones: GMP investigational product expected in early 2027; possible Controlled Human Infection Model (CHIM) study in 2028.
• Significant Market Opportunity: Addressing a growing and underserved market as Lyme disease incidence increases due to climate change and tick habitat expansion.

Detailed Report

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has announced promising results from its Phase 1 clinical trial of TNX-4800 (formerly mAb 2217LS), a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody currently in development as a single-dose prophylactic for Lyme disease. The data were presented by Dr. Mark S. Klempner, principal investigator and inventor of TNX-4800, at the World Vaccine Congress Washington 2026.

About TNX-4800

TNX-4800 is a borreliacidal (bactericidal) human monoclonal antibody engineered for an extended half-life. It targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria responsible for 99.9% of Lyme disease cases in the U.S. The antibody is expected to offer approximately four months of protection with a single subcutaneous injection, timed to cover the U.S. tick season.

This product is especially notable because there are currently no FDA-approved vaccines or single-dose prophylactics for Lyme disease, despite the significant at-risk population (estimated at 87 million Americans living, working, or vacationing in endemic regions).

Phase 1 Study Results

• Design: Double-blind, sequential dose-escalation in healthy adults (19-65 years), with 44 subjects receiving a single SC dose of placebo or TNX-4800 at 0.5, 1.5, 5, or 10 mg/kg.
• Safety: No significant clinical or laboratory safety signals. Most adverse events were mild or moderate. Anti-drug antibodies detected in less than 10% of subjects, with no effect on pharmacokinetics.
• Pharmacokinetics:
  • Peak serum concentrations (Cmax) increased ~25-fold for a 20-fold increase in dose.
  • Serum TNX-4800 was measurable as soon as two days post-injection, indicating rapid absorption.
  • Antibody levels remained quantifiable for over 200 days at the lowest dose and up to 350 days at higher doses (≥1.5 mg/kg).
  • Mean half-life ranged from 62-69 days across cohorts; maximum half-life up to 104 days.
  • In the 5 mg/kg group, mean serum TNX-4800 concentration at four months was 10 μg/ml—about double the minimum effective concentration (MEC).
• Immunity: The study showed potentially protective blood levels at two days post-dose and sustained levels for at least four months.

Advantages Over Vaccines and Other Approaches

• Faster onset of protection compared to current vaccine candidates, which require >6 months and complex schedules.
• Single dose with passive immunity, bypassing the need for the patient’s immune system to generate antibodies.
• Addresses shortcomings that led to the withdrawal of a previous anti-OspA vaccine, likely related to poor uptake due to complex scheduling.

Phase 2 Adaptive Field Study Plans

• Timing: Planned for the first half of 2027, pending FDA clearance.
• Design: Randomized, double-blind, placebo-controlled, adaptive; includes adolescents and adults (16-65 years) in Lyme-endemic U.S. regions.
• Dosing: Single 350 mg SC dose, expected to mirror exposures in the 5 mg/kg Phase 1 cohort.
• Endpoints:
  • Primary: Prevention of Lyme disease at four months (TNX-4800 vs. placebo).
  • Key Secondary: Prevention at six months.
• Other Plans: GMP investigational product available for clinical testing in early 2027; possible initiation of a controlled human infection model (CHIM) study in 2028 if necessary.

Market and Public Health Context

• Lyme disease is the most common vector-borne infection in the U.S., with incidence rising due to climate change and tick habitat expansion.
• Symptoms range from fever and rash to severe joint, cardiac, and neurologic complications if untreated. Chronic Lyme can lead to debilitating, long-term illness.
• Current treatments rely on antibiotics, but diagnosis and timely treatment are often missed, leading to chronic infection and associated costs.

Company Background and Pipeline

• Tonix is a fully integrated, commercial-stage biotech focused on CNS and immunology products.
• Its commercial infrastructure supports approved products for fibromyalgia and migraine, and its pipeline includes candidates in depression, stress disorders, Prader-Willi syndrome, prevention of kidney transplant rejection, and now, Lyme disease prophylaxis.

Potential Share Price Catalysts

• First-in-class, single-dose prophylactic for a major unmet need.
• Positive Phase 1 safety and PK data supports rapid and durable protection, de-risking future development.
• Clear, near-term clinical milestones (Phase 2 initiation in 2027, CHIM study in 2028).
• Large addressable market with no direct competition.
• Potential for significant upside if efficacy is confirmed in Phase 2 and beyond.

Investor Considerations

While the Phase 1 data are highly promising and represent a significant de-risking event, investors should remain aware of the usual risks associated with clinical-stage biotechnology companies, including regulatory, clinical, and commercial risks. The company notes the need for further capital and the inherent uncertainties in the FDA approval process.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties, including those described in Tonix Pharmaceuticals’ filings with the SEC. Clinical and regulatory outcomes are not guaranteed. Investors should perform their own due diligence and consult a qualified financial advisor before making investment decisions.

View Tonix Pharmaceuticals Holding Corp. Historical chart here